...
首页> 外文期刊>Survey of Ophthalmology >Angiogenesis and lymphangiogenesis in corneal transplantation-A review
【24h】

Angiogenesis and lymphangiogenesis in corneal transplantation-A review

机译:角膜移植中的血管生成和淋巴管发生 - 评论

获取原文
获取原文并翻译 | 示例

摘要

Corneal transplantation has been proven effective for returning the gift of sight to those affected by corneal disorders such as opacity, injury, and infections that are a leading cause of blindness. Immune privilege plays an important role in the success of corneal transplantation procedures; however, immune rejection reactions do occur, and they, in conjunction with a shortage of corneal donor tissue, continue to pose major challenges. Corneal immune privilege is important to the success of corneal transplantation and closely related to the avascular nature of the cornea. Corneal avascularity may be disrupted by the processes of angiogenesis and lymphangiogenesis, and for this reason, these phenomena have been a focus of research in recent years. Through this research, therapies addressing certain rejection reactions related to angiogenesis have been developed and implemented. Corneal donor tissue shortages also have been addressed by the development of new materials to replace the human donor cornea. These advancements, along with other improvements in the corneal transplantation procedure, have contributed to an improved success rate for corneal transplantation. We summarize recent developments and improvements in corneal transplantation, including the current understanding of angiogenesis mechanisms, the anti-angiogenic and anti-lymphangiogenic factors identified to date, and the new materials being used. Additionally, we discuss future directions for research in corneal transplantation. Published by Elsevier Inc.
机译:已经证明了角膜移植有效地将视线赠送给受角膜疾病影响的人,例如不透明度,损伤和感染,这是一个盲目的偏见。免疫特权在角膜移植程序的成功中起着重要作用;然而,免疫排斥反应确实发生,并且它们与角膜供体组织短缺,继续构成重大挑战。角膜免疫特权对于角膜移植成功并与角膜缺血性密切相关。角膜缺血性可能被血管生成和淋巴管发生的过程中断,因此,这些现象近年来一直是研究的重点。通过该研究,已经开发并实施了解决与血管生成相关的某些排斥反应的疗法。角膜捐助组织短缺也通过开发新材料来取代人体供体角膜。这些进步以及角膜移植程序的其他改进以及导角膜移植的提高成功率。我们总结了最近的角膜移植发生和改善,包括目前对血管生成机制的理解,迄今确定的抗血管生成和抗淋巴管生成因子以及正在使用的新材料。此外,我们讨论了未来的角膜移植研究方向。 elsevier公司发布

著录项

  • 来源
    《Survey of Ophthalmology》 |2018年第4期|共27页
  • 作者单位

    Jilin Univ Dept Ophthalmol China Japan Union Hosp Changchun Jilin Peoples R China;

    Univ Illinois Dept Ophthalmol &

    Visual Sci Illinois Eye &

    Ear Infirm Coll Med Chicago IL USA;

    Univ Illinois Dept Ophthalmol &

    Visual Sci Illinois Eye &

    Ear Infirm Coll Med Chicago IL USA;

    Univ Illinois Dept Ophthalmol &

    Visual Sci Illinois Eye &

    Ear Infirm Coll Med Chicago IL USA;

    Univ Illinois Dept Ophthalmol &

    Visual Sci Illinois Eye &

    Ear Infirm Coll Med Chicago IL USA;

    Univ Illinois Dept Ophthalmol &

    Visual Sci Illinois Eye &

    Ear Infirm Coll Med Chicago IL USA;

    Univ Illinois Dept Ophthalmol &

    Visual Sci Illinois Eye &

    Ear Infirm Coll Med Chicago IL USA;

    Univ Illinois Dept Ophthalmol &

    Visual Sci Illinois Eye &

    Ear Infirm Coll Med Chicago IL USA;

    Univ Illinois Dept Ophthalmol &

    Visual Sci Illinois Eye &

    Ear Infirm Coll Med Chicago IL USA;

    Univ Illinois Dept Ophthalmol &

    Visual Sci Illinois Eye &

    Ear Infirm Coll Med Chicago IL USA;

    Univ Illinois Dept Ophthalmol &

    Visual Sci Illinois Eye &

    Ear Infirm Coll Med Chicago IL USA;

    Univ Illinois Dept Ophthalmol &

    Visual Sci Illinois Eye &

    Ear Infirm Coll Med Chicago IL USA;

    Univ Illinois Dept Ophthalmol &

    Visual Sci Illinois Eye &

    Ear Infirm Coll Med Chicago IL USA;

    Univ Illinois Dept Ophthalmol &

    Visual Sci Illinois Eye &

    Ear Infirm Coll Med Chicago IL USA;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 眼科学;
  • 关键词

    corneal transplantation; corneal neovascularization; angiogenesis; lymphangiogenesis; VEGF; VEGFR; biomaterial; stem cell;

    机译:角膜移植;角膜新生血管;血管生成;淋巴管发生;VEGF;VEGFR;生物材料;干细胞;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号